Financial Instruments and Fair Value Measurements - Schedules of Concentration of Risk (Details)	3 Months Ended			9 Months Ended
	Sep. 26, 2025	Mar. 28, 2025	Sep. 27, 2024	Sep. 26, 2025	Sep. 27, 2024
Distributor concentration risk | Net sales | FFF Enterprises, Inc.
Concentration Risk
Concentration risk, percentage	23.20%		23.30%	27.40%	21.70%
Distributor concentration risk | Net sales | Cencora, Inc.
Concentration Risk
Concentration risk, percentage	18.40%			19.10%	13.70%
Distributor concentration risk | Net sales | McKesson Corporation
Concentration Risk
Concentration risk, percentage	13.50%			10.10%
Distributor concentration risk | Net sales | Cardinal Health, Inc.
Concentration Risk
Concentration risk, percentage	11.60%
Distributor concentration risk | Accounts receivable to distributors | FFF Enterprises, Inc.
Concentration Risk
Concentration risk, percentage		12.10%
Distributor concentration risk | Accounts receivable to distributors | Cencora, Inc.
Concentration Risk
Concentration risk, percentage		34.90%		36.90%
Distributor concentration risk | Accounts receivable to distributors | McKesson Corporation
Concentration Risk
Concentration risk, percentage		19.80%		22.20%
Distributor concentration risk | Accounts receivable to distributors | Cardinal Health, Inc.
Concentration Risk
Concentration risk, percentage				14.10%
Product concentration risk | Net Sales attributable to products | Acthar Gel
Concentration Risk
Concentration risk, percentage	24.10%		25.00%	28.50%	23.30%
Product concentration risk | Net Sales attributable to products | Xiaflex
Concentration Risk
Concentration risk, percentage	12.00%
Product concentration risk | Net Sales attributable to products | INOmax
Concentration Risk
Concentration risk, percentage			12.70%	11.10%	13.50%
Product concentration risk | Net Sales attributable to products | Therakos
Concentration Risk
Concentration risk, percentage			13.40%		13.00%